Navigation Links
EAU Position Statement on Screening for Prostate Cancer
Date:4/16/2009

ARNHEM, The Netherlands, April 16 /PRNewswire/ -- The European Association of Urology (EAU) has taken into consideration the recent scientific information on randomised screening studies on prostate cancer (Schröder et al, NEJM 2009). Based on the results of the European Randomised Study for Screening of Prostate Cancer (ERSPC), the EAU has formulated a position statement regarding prostate cancer screening in Europe, and the subsequent actions to be taken by health professionals and health authorities.

In summary, the ERSPC reports on a relative prostate cancer mortality reduction of at least 20% by PSA-based population screening in 162,000 asymptomatic men aged 55-69 years. For every prostate cancer death prevented, 1410 men have to undergo screening, while 48 are needed to be treated in excess of the control group population to save one prostate cancer death. Results of the PLCO (Prostate, Lung, Colon and Ovary) US randomized study of screening were also published in the same issue of the NEJM (Andriole et al, NEJM 2009) and to date show no significant effect of screening on mortality from the disease, but suffered from a significant level of contamination in the control arm. The study continues.

The EAU adopts the conclusions of the ERSPC study and recognizes the benefit of screening in terms of mortality reduction, as well as the adverse effects of overdiagnosis and overtreatment of prostate cancers which could be quantified for the first time in the setting of a randomized screening study. Further publication of relevant data is awaited from the ERSPC group in due course to inform the debate.

For the interest men's health in Europe and elsewhere, the EAU formulates the following statements:

    - Prostate cancer is a major health problem, and one of the
    main causes of male cancer deaths. However, current published data are
    insufficient to recommend the adoption of population screening for
    prostate cancer as a public health policy due to the large overtreatment
    effect. Before screening is considered by national health authorities,
    the level of current opportunistic screening, overdiagnosis,
    overtreatment, quality of life, costs, and cost-effectiveness should be
    taken into account.
    - Overdiagnosis of prostate cancer leads potentially to significant
    overtreatment. Health professionals, especially urologists, should avoid
    overtreatment by developing safe methods of cancer
    surveillance/monitoring without invasive therapy. Invasive therapies
    should be tailored to patients' needs and the prognosis of cancers
    diagnosed.
    - Current screening algorithms are insufficient due to a lack of
    specificity and lack of selectivity for aggressive cancers which require
    treatment. The development of novel diagnostic and prognostic markers and
    imaging modalities is needed urgently to enhance the predictive value of
    screening tools.
    - In the absence of population screening, the EAU advises men who
    consider screening by PSA testing and prostate biopsy to obtain
    information on the risks and benefits of screening and individual risk
    assessment.
    - The EAU and the ERSPC study group represent essential European
    stakeholders to further develop health strategies for prostate cancer
    screening.
    - The EAU promotes the quality of care for prostate cancer patients
    in Europe in collaboration with the patient support organization Europa
    Uomo http://www.europa-uomo.org) through the development of information
    and guidelines.
    - The EAU wishes to support and foster research needed to develop
    reliable active surveillance protocols for low-risk prostate cancers,
    prognostic markers, and targeted therapies in order to deliver optimal
    patient care.



'/>"/>
SOURCE European Association of Urology
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
2. Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients
3. AAOMS Updates BRONJ Position Paper
4. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
5. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
6. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
7. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
8. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
9. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
10. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
11. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
Breaking Medicine News(10 mins):